DOCSLIB.ORG

Concept and Development of a Potent Topical Corticosteroid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Concept and Development of a Potent Topical Corticosteroid FORSCHUNG 338 CI·IIMIA 46 (1992) Nr. 7/8 (Juli/Augusl) Chimia 46 (1992) 338-344 Some fifteen years ago, we have de- © Neue Schweizerische Chemische Gesellschaft cided to try to use a rational [9] approach ISSN 0009-4293 to the development of a 'superstrong' DC for an effective treatment of obstinate dermatoses which do not respond to the treatment with strong compounds, e.g. betamethasone valerate. Concept and Development Besides the classical antiinflammato- ry tests, like e.g. Tonelli's 'rat-ear-derma- of a Potent Topical titis-inhibition test' [10], a high activity of the test compounds in one of the most Corticosteroid [1][2] relevant dermato-phannacological assays - the McKenzie's 'human-skin vasocon- triction test' [11] - in a version developed in our laboratories (the HVK test) [8] was Jaroslav Kalvoda* [3][4], Jiirgen Grob [4], Klaus Jakel [5], Rene Maier [4], chosen for the characterization of DC's as Peter Moser* [5], Hermann Fuhrer [5], Erich G.Weirich [4][6], and Shantaram the primary selection criteria. J. Yawalkar [7] It has been shown in many reports about percutaneous resorption that the Ahstract. In a rational approach to identify an ultrapotent compound for the treatment flux, I, of a compound completely dis- of therapy-resistant dermatoses, Weirich's modification [8] of McKenzie's skin vaso- solved in a vehicle, through the skin is constriction assay (HVK test) has been used as the essential selection criteria. In a strongly dependent on its lipophilicity. primary phase, a quantitative relationship between the HVK activity of 25 derivatives According to Scheuplein [12], this fact of corticosterone substituted in various positions of the skeleton, and their lipophilicity can be mathematically expressed by the (log P) was established. The specific lipophilicity-independent interactions were following equation: accounted for by the inclusion of 'indicator variables' into the regression analysis. The Pm . Dm . L1(Cs) highly significant results allowed to localize an optimal log P range and to identify the I = dQ/dt = influence of various substituents. In a next phase, the evidence of the firstHVK analysis d was refined by considering 28 additional compounds. On the basis of the confirmed Pm = partitIOn coefficient stratum facts, six 21-chloro-6a-fluoro compounds were specifically synthesized and submitted corneum/vehicle to dermatopharmacological testing. Finally, CGP 14458 (= 2l-chloro-6a,9-difluoro- Dm = diffusion coefficient in stratum \1,B-hydroxy-16,B-methyl-3,20-dioxopregna-l ,4-dien-17 a-yl propionate) which was corneum predicted to be the most potent representative of these series, whose synthesis is L1(Cs)= difference in concentration described in detail, showed indeed to be the most effective compound. Clinical trials through the stratum corneum with this compound - halobetasol propionate/Ultravate® (ulobetasol/Miracorten®) - d = diameter of the stratum cor- confirmed its unique efficacy, especially in the treatment of severe, chronic plaque neum psoflasls. General 21 OR1 21 X The corticosteroid hormones produced o by the adrenals, as well as their more potent synthetic analogues, are represent- ing a type of compounds of vital impor- Q tance to men, showing a very broad spec- trum of activity. o During the past decades, beside the ;6 Y classical systemic application of gluco- corticosteroids, which, in spite of the great Series: HYDROCORTISONE Series: DEXA-I FLUMETHASONE popularity ofNSAID's, is still considered to be the essential treatment of many life- threatening diseases, there have been in- 21 OR troduced into therapy the so-called derma- 21 X tocorticoids (DC). Their use for the topi- o cal treatment of skin allergies, inflamma- tions, and proliferating dermatoses of the human skin has become indispensable. o ~6 o Y Series: TRIAMCINOLONE I Series: BETAMETHASONE Correspondence: Dr. J. KalvodalDr. P. Moser FLUOCINOLONE Ciha-Geigy AG [Q, Y, Z = H, Hal; X = CI, OAe, OH; R, Rl' R2 = H, Ae; R1+A1 = C(CH3)2] K-136.P21jK-24.U.103 CH-4002 Basel FORSCHUNG 339 CHI MIA 46 (1992) Nr. 7/8 (JlIli/AlI~usl) In a steady state, the amount of the compound transported per time unit log Wrel through the skin is proportional to the 3.0 - partition coefficient between the vehicle • and the stratum corneum. .,,-,--- .--.---- 2.5 " We have, therefore, decided to try to ,,,' . deduce in the first part of our study a . ,,//: ~. quantitative correlation between the HVK 2.0 .~ ~. // .. activity of the test compounds and their ,,". lipophilicity expressed as partition coeffi- 1.5 ., "" cients in the system octanol1H 0, which is " 2 " believed to mimic the in vivo situation .." 1.0 ,I" best. I I For the first step of our investigation, I I I we have selected a series of 25 steroids 0.5 / I belonging to four different groups of DC ' s, 1 Fig. I. 1st HVK Test namely, those of hydrocortisone (HC), / . o I (human skin \'asocon- dexamethasonelflumethasone, triamci- I. strictio11assay). DMWDIIC nolonelfluocinolone and betamethasone. Iog Wrei = Iog DMV,ib= The lipophilicity has been manipulated 1.0 2D 3.0 4.0 log P -2.79 + 2.36 log P mainly by variation of the substituents in -0.28 (log P)2; 11 = 25, positions 2, 9, and 21 ofthe steroid nucle- I' = 0.862, s = 0.470. us. In (Figs. 1-4), the logarithms of the relative potencies, log Wrei' are plotted against the log P values of the compounds. log Wrel In spite of the relative large deviations of 3.0 the single points from the parabola calcu- lated by multiple regression, a clear-cut dependence is observed between the vaso- constrictor activity and the log P value. In 2.0 addition, a presumably optimal log P area can be observed in the range of about 3.5- 4.5. The next step consisted in a refinement 1.0 of the regression by inclusion of indicator variables in the so-called mixed Hansch- Free- Wilson approach [13]. Indicator var- Fig. 2.1 st HVKTest. Com- puted values corrected by iab~es, X .' are discrete variables which 0.0 ij the increments of the sub- can assume the value of either 0 or 1, stituents deduced from describing thereby the presence or ab- mixed analysis. log W rei = sence of a specific substituent. The corre- -1.59 + 1.29 log P - 0.13 -1.0 (logP)2+0.70(6-F)+ 1-02 sponding coefficients, Aij, calculated by 1.0 2.0 3.0 multiple linear regression express the con- 4.0 5.0 log P (l6/i-CH3) + 0.42 (16,17- tributions of the particular substituents to Aeetonid); 11 = 25,1'=0.96, s = 0.306. the overall activity. By admixing the log P, a separation can be achieved between the Iipophilicity-dependent contributions and specific interactions of the substituents at synthesize new derivatives, whose vaso- clobetasol propionate (CGP 9'555), the the molecular level. In our specific analy- constrictor activity would be expected to active ingredient of Glaxo's Dermovate®' sis, it has been shown that only the 6a- be distinctly superiorto that of compounds The inclusion of indicator variables leads fluorine, the 16,B-Me group, and the 16,17- which we have already tested. Of special to the shown equation (Fig. 4) [14]. acetonide grouping give statistically sig- interest appeared to be the fact that a 6a- The correlation having an R value nificant contributions and have, therefore, F substituent having a strong positive ef- of 0.98 and a standard deviation of s = to be considered. fect upon the activity, showed no measur- 0.29 can be considered as highly satisfac- As is shown in Fig. 2, the standard able contribution to the lipophilicity. tory. deviation, after introducing the above dis- In the second analysis, there have been Below, there are reproduced the struc- cussed corrections, is clearly in the region included 28 additional compounds. As tures of the six already mentioned com- of the reproducibility of the biological mentioned before, particular attention has pounds showing a particularly high activ- data. This very positive result, combined been payed to the 6a-F compounds. ity in the HVK test and differing in respect with the relatively strict additivity of the The relative potencies, log W rei'shown to their configuration at C(l6), the substi- log P contributions of the individual sub- in Fig. 3 as a function of log P, are situated tution at C(2) and C(9) and in the number stituents on the steroid skeleton, and, there- in the expected range. The points carrying of C=C bonds. fore, with the calculability of the integral a CGP number correspond to six inten- They were subjected to an extended log P value of the compound, allowed us in tionally synthesized compounds and to secondary screening and compared with the second series of our experiments to the most active DC known up today - to each other in respect to activity and side FORSCHUNG 340 CHIMIA 46 (1992) Nr. 7/8 (Juli/AuguSl) effects. A synopsis of the results obtained activity is represented in this graph as a Beclomethasone [20] (1) appeared to in the 4 most important dermatophar- percentage of the factor 2000 x He. The be an ideal starting material for the planned macological tests [15] is presented in Fig. second parameter is a measure for the synthesis. The corresponding orthoester 2 5. intensity of the blanching reaction. generated 9p, 11-epoxide 3, which was The UV -dermatitis inhibition test in On the basis of these data and of the selectively hydrogenated in position 1(2) guinea pigs as well as the 'croton-oil- results of skin tolerability tests, CGP 14'458 under the known conditions of homoge- dermatitis-inhibition test' in rabbits do not (ulobetasol [l6]/Miracorten®; halobeta- neous catalysis in dioxane solution, to permit a clear differentiation of the com- sol propionate [17]/Ultravate® [18]) has yield the mono-unsaturated ketone 4.
Load more

Recommended publications
  • Role of Corticosteroids in Treatment of Vitiligo
    Chapter 9 Role of Corticosteroids in Treatment of Vitiligo Nooshin Bagherani Additional information is available at the end of the chapter http://dx.doi.org/10.5772/48384 1. Introduction Vitiligo is the most frequent pigmentary disorder ( Bagherani et al., 2011; Nazer et al., 2011;Yaghoobi et al., 2011a; as cited in Wolff et al., 2007). It is an acquired, idiopathic and progressive skin disease (Bagherani et al., 2011; Shameer et al., 2005; Yaghoobi et al., 2011a), characterized by sharply demarcated depigmented lesions on any part of the body (Van Geel et al., 2004). This disease can also affect hair and mucosal areas such as mouth and genitalia (Gawkrodger et al., 2010). Vitiligo usually begins after birth (Gawkrodger et al., 2010). Regarding the studies retrieved from PubMed since 1995, it has been shown that approximately 50% of the vitiligo cases have its onset before the age of 20 years and 25% before the age of 14 years (Kakourou, 2009). The incidence rate of vitiligo is between 0.1-2% of the world population ( Bagherani et al., 20011; Yaghoobi et al., 2011a,b; as cited in Alkhateeb et al., 2003). Its incidence in those with racially pigmented skin is higher, although reliable figures are not available (Burns et al., 2004; Howitz et al., 1977) . The prevalence has been reported as high as 4% in some South Asian, Mexican and American populations ( Parsad et al., 2003; Sehgal & Srivastava, 2007; Szczurko & Boon, 2008). Both sexes are equally afflicted by vitiligo (Krϋger et al., 2011; Njoo & Westerhof, 2001; Wolf et al.,2007) . In some studies, a female preponderance has been reported ( Burns at al., 2004; Howitz et al.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • 2018 Medicines in Development for Skin Diseases
    2018 Medicines in Development for Skin Diseases Acne Drug Name Sponsor Indication Development Phase ADPS topical Taro Pharmaceuticals USA acne vulgaris Phase II completed Hawthorne, NY www.taro.com AOB101 AOBiome acne vulgaris Phase II (topical ammonia oxidizing bacteria) Cambridge, MA www.aobiome.com ASC-J9 AndroScience acne vulgaris Phase II (androgen receptor degradation Solana Beach, CA www.androscience.com enhancer) BLI1100 Braintree Laboratories acne vulgaris Phase II completed Braintree, MA www.braintreelabs.com BPX-01 BioPharmX acne vulgaris Phase II (minocycline topical) Menlo Park, CA www.biopharmx.com BTX1503 Botanix Pharmaceuticals moderate to severe acne vulgaris Phase II (cannabidiol) Plymouth Meeting, PA www.botanixpharma.com CJM112 Novartis Pharmaceuticals acne vulgaris Phase II (IL-17A protein inhibitor) East Hanover, NJ www.novartis.com clascoterone Cassiopea acne vulgaris Phase III (androgen receptor antagonist) Lainate, Italy www.cassiopea.com Medicines in Development: Skin Diseases ǀ 2018 Update 1 Acne Drug Name Sponsor Indication Development Phase CLS001 Cutanea acne vulgaris Phase II (omiganan) Wayne, PA www.cutanea.com DFD-03 Promius Pharma acne vulgaris Phase III (tazarotene topical) Princeton, NJ www.promiuspharma.com DMT310 Dermata Therapeutics moderate to severe acne vulgaris Phase II (freshwater sponge-derived) San Diego, CA www.dermatarx.com finasteride Elorac severe nodulocystic acne Phase II (cholestenone 5-alpha Vernon Hills, IL www.eloracpharma.com reductase inhibitor) FMX101 Foamix moderate to severe
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0099225A1 Freund Et Al
    US 20090099225A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0099225A1 Freund et al. (43) Pub. Date: Apr. 16, 2009 (54) METHOD FOR THE PRODUCTION OF Related U.S. Application Data PROPELLANT GAS-FREE AEROSOLS FROM (63) Continuation of application No. 1 1/506,128, filed on AQUEOUSMEDICAMENT PREPARATIONS Aug. 17, 2006, now Pat. No. 7,470,422, which is a continuation of application No. 10/417.766, filed on (75) Inventors: Bernhard Freund, Gau-Algesheim Apr. 17, 2003, now abandoned, which is a continuation (DE); Bernd Zierenberg, Bingen of application No. 09/331,023, filed on Sep. 15, 1999, am Rhein (DE) now abandoned. (30) Foreign Application Priority Data Correspondence Address: MICHAEL P. MORRIS Dec. 20, 1996 (DE) ............................... 19653969.2 BOEHRINGERINGELHEMI USA CORPORA Dec. 16, 1997 (EP) ......................... PCT/EP97/07062 TION Publication Classification 900 RIDGEBURY RD, P. O. BOX 368 RIDGEFIELD, CT 06877-0368 (US) (51) Int. Cl. A63L/46 (2006.01) (73) Assignee: Boehringer Ingelheim Pharma A63L/437 (2006.01) KG, Ingelheim (DE) (52) U.S. Cl. ......................................... 514/291; 514/299 (57) ABSTRACT (21) Appl. No.: 12/338,812 The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propel (22) Filed: Dec. 18, 2008 lant-free aerosols. US 2009/0099225A1 Apr. 16, 2009 METHOD FOR THE PRODUCTION OF 0008 All substances which are suitable for application by PROPELLANT GAS-FREE AEROSOLS FROM inhalation and which are soluble in the specified solvent can AQUEOUSMEDICAMENT PREPARATIONS be used as pharmaceuticals in the new preparations. Pharma ceuticals for the treatment of diseases of the respiratory pas RELATED APPLICATIONS sages are of especial interest.
    [Show full text]
  • Different Strategies for Using Topical Corticosteroids in People with Eczema (Protocol)
    Cochrane Database of Systematic Reviews Different strategies for using topical corticosteroids in people with eczema (Protocol) Chalmers JR, Axon E, Harvey J, Santer M, Ridd MJ, Lawton S, Langan S, Roberts A, Ahmed A, Muller I, Long CM, Panda S, Chernyshov P, Carter B, Williams HC, Thomas KS Chalmers JR, Axon E, Harvey J, Santer M, Ridd MJ, Lawton S, Langan S, Roberts A, Ahmed A, Muller I, Long CM, Panda S, Chernyshov P, Carter B, Williams HC, Thomas KS. Different strategies for using topical corticosteroids in people with eczema. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD013356. DOI: 10.1002/14651858.CD013356. www.cochranelibrary.com Different strategies for using topical corticosteroids in people with eczema (Protocol) Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 4 METHODS ...................................... 4 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 12 CONTRIBUTIONSOFAUTHORS . 13 DECLARATIONSOFINTEREST . 14 SOURCESOFSUPPORT . 15 Different strategies for using topical corticosteroids in people with eczema (Protocol) i Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Different strategies for using topical corticosteroids in
    [Show full text]
  • Effect of Different Skin Penetration Promoters in Halobetasol Propionate Permeation and Retention in Human Skin
    International Journal of Molecular Sciences Article Effect of Different Skin Penetration Promoters in Halobetasol Propionate Permeation and Retention in Human Skin Paulina Carvajal-Vidal 1,2,* ID , Mireia Mallandrich 1 ID , María Luisa García 1,2 and Ana Cristina Calpena 1,2 ID 1 Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain; [email protected] (M.M.); [email protected] or [email protected] (M.L.G.); [email protected] (A.C.C.) 2 Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain * Correspondence: [email protected]; Tel.: +34-657-133227 Received: 29 October 2017; Accepted: 17 November 2017; Published: 21 November 2017 Abstract: Halobetasol propionate (HB) is a potent synthetic corticosteroid used against inflammatory skin diseases, such as dermatitis, eczema, and psoriasis, among others. The aim of this study is to define how the presence of different skin penetration enhancers (nonane, menthone, limonene, azone, carene, decanol, linoleic acid and cetiol) affects the penetration and retention in skin of HB. To determine drug penetration through skin, 5% of each promoter was used in an ex vivo system with human skin on Franz cells. The results showed that the highest permeation occurs in the presence of menthone, followed by nonane. Permeation parameters were determined. The in vivo test was assessed, and the formulation containing HB-menthone presented better anti-inflammatory efficacy. These results are useful to generate a specific treatment according to each patient’s needs, and the inflammatory characteristics of the disease. Keywords: halobetasol propionate; permeation enhancers; skin permeation; skin inflammation; topical corticosteroid 1.
    [Show full text]
  • ULTRAVATE® Product Monograph Page 2 of 27
    PRODUCT MONOGRAPH Tri-halogenated PrULTRAVATE® Halobetasol Propionate Topical Cream 0.05 % w/w Halobetasol Propionate Topical Ointment 0.05 % w/w Topical Corticosteroid Bausch Health, Canada Inc. Date of Revision: 2150 St-Elzear Blvd., West October 15, 2019 Laval, Quebec, H7L 4A8 Canada Submission Control No: 230873 NAME OF DRUG PrULTRAVATE® Halobetasol Propionate Topical Cream 0.05 % w/w Halobetasol Propionate Topical Ointment 0.05 % w/w THERAPEUTIC CLASSIFICATION Topical Corticosteroid INDICATIONS AND CLINICAL UES ULTRAVATE® (halobetasol propionate) Cream and Ointment are high to super-high potency topical corticosteroids indicated for the relief of inflammatory manifestations of resistant or severe psoriasis and corticosteroid-responsive dermatoses. These products are not recommended for use in children. CONTRAINDICATIONS ULTRAVATE® (halobetasol propionate) Cream and Ointment are contraindicated in patients who are hypersensitive to halobetasol propionate, to other corticosteroids, or to any of the ingredients in these products. ULTRAVATE® (halobetasol propionate) Cream and Ointment are contraindicated in viral diseases of the skin including herpes simplex, vaccinia and varicella. They are also contraindicated in untreated bacterial, tubercular and fungal infections involving the skin. WARNINGS Use in Pregnancy There are no clinical trials of ULTRAVATE® in pregnant women. Therefore, this product should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Corticosteroids have been shown to be teratogenic and embryotoxic in laboratory animals at low doses when administered systemically. Some corticosteroids have been shown to be teratogenic after topical application. Halobetasol propionate has been shown to be teratogenic in rats and rabbits at low doses. The human topical dose of ULTRAVATE ® was embryotoxic in rabbits.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Stability of Betamethasone Esters in Some Topical Dosage Forms and Its Impact on Their Biological Potential
    STABILITY OF BETAMETHASONE ESTERS IN SOME TOPICAL DOSAGE FORMS AND ITS IMPACT ON THEIR BIOLOGICAL POTENTIAL Thesis submitted in partial fulfillment of the requirement for the degree of DOCTOR OF PHILOSOPHY by Saif-ur-Rehman Khattak B.Pharm, M.Pharm SUPERVISOR: PROF. DR. DILNAWAZ SHEIKH CO-SUPERVISOR: PROF. DR. USMAN GHANI KHAN Faculty of Pharmacy HAMDARD UNIVERSITY Karachi – 74600 March 2010 iii ABSTRACT The present work involves an investigation of the thermal and photochemical degradation of betamethasone esters i.e. betamethasone valerate and betamethasone dipropionate under various conditions and the evaluation of the photoxicity of these compounds. The thermal degradation (40 oC) of betamethasone-17-valerate leads to the formation of betamethasone-21-valerate and betamethasone alcohol whereas betamethasone dipropionate gives rise to betamethasone-17-propionate, betamethasone-21-propionate and betamethasone alcohol at pH 2.5-7.5, betamethasone-21-propionate being an intermediate in this reaction. The betamethasone esters on photodegradation, using a UV radiation source (300-400nm), yield two major unknown products in aqueous and organic solvents. The detection of the photodegradation products of betamethasone valerate and betamethasone dipropionate has been carried out by HPLC and the t R values of the unknown products have been reported. The USP HPLC method, after proper validation, has been used for the assay of betamethasone esters and their thermal and photodegradation products. The analytical data have been used to evaluate the kinetics of thermal and photochemical reactions. In both reactions the betamethasone esters have been found to follow the first-order kinetics under the conditions employed. The apparent first-order rate constants for the thermal degradation of betamethasone valerate and betamethasone dipropionate in various media lie in the range of 0.339-9.07x10 -3 hr -1 and 0.239-1.87x10 -3 hr -1, respectively.
    [Show full text]
  • Finished Dosage Forms
    United States Product List - Finished Dosage Forms Molecule Dosage form Molecule Dosage form Palonosetron Liquid In Vial Valaciclovir Tablet, Film-Coated Amoxicillin Hard Gelatine Capsule Voriconazole Tablet, Film-Coated Amoxicillin Powder For Oral Suspension Voriconazole Lyophilisate In Vial Amoxicillin Tablet Benazepril Hydroch. + Hydrochlorothiazide Tablet, Film-Coated Amoxicillin Trihydrate Powder For Oral Suspension Bumetanide Tablet Amoxicillin Trihydrate Powder For Oral Suspension Enalapril Maleate Tablet Amoxicillin Trihydrate + Pot. Clavulanate Powder For Oral Suspension Ephedrine Liquid In Vial Amoxicillin Trihydrate + Pot. Clavulanate Tablet, Film-Coated Ezetimibe Tablet Amoxicillin Trihydrate + Pot. Clavulanate Powder For Oral Suspension Isosorbide Dinitrate Tablet Ampicillin Vial Labetalol Hydrochloride Tablet, Film-Coated Azithromycin Dihydrate Tablet, Film-Coated Norepinephrine Liquid In Vial Cefazolin Vial Phenylephrine Liquid In Vial Ceftriaxone Vial Rosuvastatin Calcium Tablet, Film-Coated Clarithromycin Tablet, Film-Coated Alprazolam Tablet Levofloxacin Tablet, Film-Coated Amitriptyline Hydrochloride Tablet, Film-Coated Nafcillin Vial Clomipramine Hydrochloride Hard Gelatine Capsule Nevirapine Tablet, Prolonged Release Desipramine Hydrochloride Tablet Nitrofurantoin Hard Gelatine Capsule Dexamphetamine + Amphetamine Tablet Penicillin G Vial Hydroxychloroquine Sulphate Tablet Piperacillin Tazobactam Vial Oxaprozin Tablet, Film-Coated Tigecycline Lyophilisate In Vial Quetiapine Fumarate Tablet, Film-Coated Product exploitation,
    [Show full text]
  • Previous Versions
    bmjpo: first published as 10.1136/bmjpo-2020-000893 on 5 January 2021. Downloaded from BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay- per-view fees (http://bmjpaedsopen.bmj.com). If you have any questions on BMJ Paediatrics Open’s open peer review process please email [email protected] http://bmjpaedsopen.bmj.com/ on September 25, 2021 by guest. Protected copyright. BMJ Paediatrics Open bmjpo: first published as 10.1136/bmjpo-2020-000893 on 5 January 2021. Downloaded from Confidential: For Review Only Examining the effects of excess pre-pregnancy weight and gestational weight gain on allergic disease development in offspring: a protocol for a population-based study using health administrative databases in Ontario, Canada Journal:
    [Show full text]
  • Study Protocol
    Clinical Study Protocol Effect of Calcipotriol plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 months) with Scalp and Body Psoriasis A phase 2 trial evaluating the safety and efficacy of once daily use of LEO 80185 gel containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis An international, multi-centre, prospective, non-controlled, open, single-group, 8-week trial in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis ICH GCP statement: The clinical trial will be conducted in compliance with the Clinical Study Protocol, GCP and the applicable regulatory requirement(s). LEO Pharma A/S Protocol Code Number: LP0076-1017 Global Clinical Operations Date: 17-Apr-2013 Version: 1 EudraCT Number: 2013-001538-16 eDoc-00341337 - Version 2.0 LP0076-1017 17- Apr-2013 Page 2 of 123 1 Clinical Study Protocol Approval/ Ackno wledge 1. 1 Approval State ment L E O Phar ma A/S O n b e h alf of L E O P h ar m a A/ S, o nl y t h e h e a d of M e di c al D e p art m e nt a n d t h e h e a d of Bi ost atisti cs a n d D at a M a n a g e m e nt ar e a ut h oris e d t o a p pr o v e t h e Cli ni c al St u d y Pr ot o c ol a n d C o ns oli d at e d Cli ni c al St u d y Pr ot o c ol(s) co mprising any subsequent a mend ment(s).
    [Show full text]